# US 2026/0263830 A1 · Optogenetic modulation of central nervous system for treating pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263830 A1
- Document ID: US20260263830A1
- Status: Published application
- Kind: A1
- Application number: 19/157,653
- Filed: 2024-02-20
- Published: 2026-09-10
- Earliest claimed: 2023-02-20
- Assignees: Opsin Biotherapeutics, Inc.
- Applicants: Opsin Biotherapeutics, Inc.
- Inventors: Samarendra Kumar Mohanty; Darryl Narcisse; Robert BENKOWSKI
- Web page: https://patentgrep.com/patent/US20260263830A1

## CPC

- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61N 5/0601: {Apparatus for use inside the body}
- A61N 5/0622: {Optical stimulation for exciting neural tissue}
- A61N 5/067: using laser light
- A61P 29/02: without antiinflammatory effect
- A61N 2005/063: {comprising light transmitting means, e.g. optical fibres}
- A61N 2005/0651: {Diodes}
- A61N 2005/0662: {Visible light}
- A61N 2005/0663: {Coloured light}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates generally to compositions and methods for modulating cellular activities using multi-characteristic opsin (MCO). Further, the invention provides methods for treating ailments related to activity of the dorsal root ganglia (DRG), anterior cingulate cortex (ACC) or spinal cord including neuropathic pain. Specific embodiments include methods of modulating inhibitory pathways to inhibit chronic neuropathic pain. The methods can use a light sensitive optogenetic actuator with inhibitory neuron specificity. Embodiments also include an optogenetic pain modulator device that can regulate the frequency and intensity of optogenetic stimulation.

## Claims

### Claim 1

An optogenetic stimulation apparatus for use in a method of inhibiting pain by targeting inhibitory cells with an excitatory light-sensitive protein in a subject suffering from pain, the apparatus comprising an optogenetic stimulation device for emitting light and controlling the emission of the light, and a recombinant nucleic acid encoding an excitatory light-sensitive protein, wherein the method comprising steps of:
a) expressing the recombinant nucleic acid encoding the excitatory light-sensitive protein in inhibitory neural cells of the subject, and
b) controlling expression of the excitatory light-sensitive protein in GABAergic inhibitory cells by use of a GAD promoter to modulate neural activity of the inhibitory cells with light generated by the optogenetic stimulation device,
wherein the modulation reduces the duration and/or intensity of the pain.

### Claim at position 2

2-61. (canceled)

### Claim 62 (depends on 1)

The optogenetic stimulation apparatus of claim 1, wherein the inhibitory neural cells are spinal cord cells, dorsal root ganglioa (DRG) cells, and/or anterior cingulate cortex (ACC) cells.

### Claim 63 (depends on 1)

The optogenetic stimulation apparatus of claim 1, wherein the excitatory light-sensitive protein is a multi-characteristic opsin (MCO).

### Claim 64 (depends on 63)

The optogenetic stimulation apparatus of claim 63, wherein the multi-characteristic opsin (MCO) has at least 80% identity to SEQ ID NO. 1.

### Claim 65 (depends on 1)

The optogenetic stimulation apparatus of claim 1, wherein the pain is one or more of neuropathic pain, inflammatory pain, headache pain, somatic pain visceral pain and referred pain.

### Claim 66 (depends on 65)

The optogenetic stimulation apparatus of claim 65, wherein the neuropathic pain is chronic neuropathic pain and/or caused by one or more of a traumatic insult, a spinal cord injury, a limb amputation, a contusion, an inflammation or a surgical procedure, an ischemic event, an infectious agent, exposure to a toxic agent or a disease.

### Claim 67 (depends on 1)

The optogenetic stimulation apparatus of claim 1, comprising a viral vector or non-viral vector for use in the step of expressing a recombinant nucleic acid encoding a light-sensitive protein in the inhibitory neural cells of the subject.

### Claim 68 (depends on 1)

The optogenetic stimulation apparatus of claim 1, comprising one or more optical fiber and wherein the method further comprising a step of implanting the one or more optical fiber into the subject to control light activation of the light-sensitive protein, optionally wherein the one or more optical fiber is operable to be activated from a wireless signal, and optionally wherein the one or more optical fiber is configured to be implanted charged, or be powered wirelessly.

### Claim 69 (depends on 68)

The optogenetic stimulation apparatus of claim 68, wherein the light is a low-power red light, optionally wherein the light has a wavelength of about 635 nm.

### Claim 70 (depends on 1)

The optogenetic stimulation apparatus of claim 1 for use in a method of inhibiting neuropathic pain in a subject without affecting nociceptive pain,
wherein light activation of the excitatory light-sensitive protein reduces the duration and/or intensity of the neuropathic pain.

### Claim 71 (depends on 1)

The optogenetic stimulation apparatus of claim 1 for use in a method of treating an ailment in a subject in need thereof, wherein the modulation adjusts the excitation to inhibition (E/I) balance of the inhibitory neural cells of the subject.

### Claim 72 (depends on 62)

The optogenetic stimulation apparatus of claim 62, wherein the ailment is a neurological disorder selected from one or more of the fibromyalgia, rheumatoid arthritis, osteoarthritis, chronic arthropathy, spinal nerve compression syndromes associated with neoplasia and/or disc herniation, chronic back pain, chronic joint pain of any etiology associated with inflammation and/or structural joint abnormalities, post-herpetic neuralgia, trigeminal neuralgia, chronic metabolic neuropathy associated with chronic pain, migraine, inflammatory pain, post-surgical pain syndromes including phantom limb pain, post-traumatic stress disorder (PTSD), irritable bowel syndrome, autonomic neuropathies, arachnoiditis, chronic regional pain syndrome, vulvodynia, and chronic pain syndrome associated with activation of central sensitization pathways, visual impairment, drug addiction, a psychological disorder, and a movement disorder.

### Claim 73 (depends on 62)

The optogenetic stimulation apparatus of claim 62, wherein the persistence of therapy is maintained by modulating light parameters, optionally wherein the light parameters are at least one selected from intensity, duty cycle, and periods.

### Claim 74 (depends on 1)

The optogenetic stimulation apparatus of claim 1 for use in a method of reducing pain in a subject, wherein the optogenetic stimulation device is wireless, and the method comprising steps of:
a) transfecting the inhibitory neural cells of the subject with a virus to express the excitatory light-sensitive protein;
b) implanting the wireless optogenetic stimulation device at or near the inhibitory neural cells, the spinal cord, ACC or DRG of the subject; and
c) activating the excitatory light-sensitive protein in specific inhibitory neural cells in the spinal cord, ACC or DRG with light emitted from the optogenetic stimulation device to reduce pain.

### Claim 75 (depends on 65)

The optogenetic stimulation apparatus of claim 65, wherein the light is emitted in pulses with a width from 1 to 100 milliseconds and a duty cycle from 1 to 100 percent, and tuned to a light intensity up to 100 mW/mm2.

### Claim 76

A method of inhibiting pain by targeting inhibitory cells with an excitatory light-sensitive protein in a subject suffering from pain, the method comprising steps of:
a) expressing a recombinant nucleic acid encoding the excitatory light-sensitive protein in inhibitory neural cells of the subject, and
b) controlling expression of the excitatory light-sensitive protein in GABAergic inhibitory cells by use of a GAD promoter to modulate neural activity of the inhibitory cells with light,
wherein the modulation reduces the duration and/or intensity of the pain, and using an LED light source for generating the light, optionally comprising fiber optic(s).

### Claim 77 (depends on 67)

The method of claim 67, wherein the inhibitory neural cells are spinal cord cells, dorsal root ganglioa (DRG) cells, and/or anterior cingulate cortex (ACC) cells.

### Claim 78 (depends on 67)

The method of claim 67, wherein the excitatory light-sensitive protein is a multi-characteristic opsin (MCO), optionally wherein the multi-characteristic opsin (MCO) has at least 80% identity to SEQ ID NO. 1.

### Claim 79 (depends on 67)

The method of claim 67, wherein the pain is one or more of neuropathic pain, inflammatory pain, headache pain, somatic pain visceral pain and referred pain, optionally wherein the neuropathic pain is chronic neuropathic pain and/or caused by one or more of a traumatic insult, a spinal cord injury, a limb amputation, a contusion, an inflammation or a surgical procedure, an ischemic event, an infectious agent, exposure to a toxic agent or a disease.

### Claim 80 (depends on 67)

The method of claim 67, wherein a light source for generating the light is implanted or transdermal, and the light is a low-power red light, optionally wherein the light has a wavelength of about 635 nm.
